Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVD-130850 as Single Agent and in Combination With Pembrolizumab in Advanced Solid and Hematologic Tumors
NCT06188208Phase 1Terminated
- Sponsor
- Vividion Therapeutics
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of VVD-130850 in solid tumor and non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Vividion Therapeutics. Primary endpoints: Incidence and Severity of Dose-limiting Toxicities, Number of Participants with Adverse Events and Serious Adverse Events and 2 more. Started Jan 2024; status: terminated.
02
Drugs
VVD-130850
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06188208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06188208.